Paris, France, 10 July, 2024 - MicroPort® NeuroTech™ recently completed the first two commercial implantations of its NUMEN® Coil Embolization System (NUMEN®) in Paris, France. Prior to these procedures, NUMEN® underwent evaluation by France's National Health Authority (HAS) and secured a health insurance reimbursement code.
The first patient was preoperatively diagnosed with an unruptured saccular aneurysm in cavernous sinus segment of the left internal carotid artery. During the procedure, the surgeon utilized five NUMEN® Coils for filling and finishing, noting their smooth detachment. The second patient had an unruptured aneurysm measuring approximately 7.5 x 17.7 mm in the C3 segment of the right internal carotid artery. The surgeon employed various Numen® Coils throughout the stages of basket construction, filling, and finishing.
In both cases, NUMEN® demonstrated stable framing ability, strong space-seeking capabilities, good packing density, and a low risk of coil protrusion.
Previously, the NUMEN® range – including NUMEN® Frame, NUMEN® Fill, and NUMEN® Finish - obtained HAS approval and reimbursement codes in April and October 2023, respectively. This significant advancement aims to alleviate patient financial burdens and expedite market acceptance in France, benefiting more patients.
NUMEN ® was approved for marketing in China in September 2020. It also holds CE MDR approval in Europe, FDA approval in the United States, MFDS approval in Korea, ANVISA approval in Brazil, and MHLW approval in Japan. NUMEN® features 177 specifications of varying lengths and diameters, allowing for precise treatment tailored to different aneurysm cases through a minimally invasive approach. It aims to thrombose aneurysms over the medium to long term while mitigating risks associated with open surgery. Its ultra-fine platinum-tungsten coil and unique 3D structure offer a combination of flexibility and support, suitable for treating aneurysms of diverse shapes.
MicroPort® NeuroTech™ remains committed to advancing global medical research and development for the comprehensive treatment of cerebrovascular diseases, thereby providing high quality and accessible total medical solutions for patients worldwide.
About MicroPort® NeuroTech™
MicroPort® NeuroTech™ (MicroPort NeuroTech Limited; HKEX: 2172) , an associated company of MicroPort® (MicroPort Scientific Corporation; HKEX: 00853), is committed to the research and development of high-end medical devices in the field of neurological interventional treatment with solutions that currently support over 100 cerebrovascular stenting procedures every day. In the future, MicroPort® NeuroTech™ will continue investing more resources in innovation and development to provide more high-quality and innovative cerebrovascular and neuro intervention solutions for doctors and patients.
More information is available at www.medneurotech.com.